MindMed Announces Exclusive License Agreement With Catalent For Its Patented Zydis Fast-Dissolve Technology For Use With MM-120
Portfolio Pulse from Happy Mohamed
Mind Medicine (MindMed) Inc has entered into a license agreement with Catalent to access its proprietary Zydis orally disintegrating tablet (ODT) technology. The agreement grants MindMed exclusive rights to use the Zydis technology for the development of its lead product candidate MM-120 in the US, UK, and EU among other territories. MindMed is currently conducting a Phase 2b trial evaluating MM-120 for the treatment of generalized anxiety disorder with topline data expected in Q4 2023.
August 04, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MindMed's new license agreement with Catalent for its Zydis technology could potentially enhance the development of its lead product MM-120. This could strengthen MindMed's competitive advantage in the market.
The license agreement with Catalent allows MindMed to use the Zydis technology, which could enhance the bioavailability and absorption of MM-120. This could potentially result in a shorter treatment session for MM-120, enhancing MindMed's competitive advantage in the market. Furthermore, the ongoing Phase 2b trial for MM-120 could also positively impact MindMed's stock if the results are favorable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100